Home › Leucemia linfatica cronica › Wisconsin
Studi clinici su Leucemia linfatica cronica nello stato di Wisconsin
19 studi su Leucemia linfatica cronica cercano partecipanti presso sedi nello stato di Wisconsin.
Città nello stato di Wisconsin
Testo ufficiale dello studio (inglese)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- e altri 7
In reclutamentoFase 3
Età 65 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- e altri 50
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- Duluth Clinic Ashland, Ashland
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- e altri 14
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT04269902A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Gunderson Health System, La Crosse
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048), Madison
- University Hospital and UW Health Clinics ( Site 0006), Madison
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- The Medical College of Wisconsin, Milwaukee
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07221500Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT03666000A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 lug 2026 · NCT05131022Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT07218510A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 mar 2026 · NCT06876649CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
In reclutamentoFase 1/2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 23 feb 2026 · NCT04186520Study of SGR-1505 in Mature B-Cell Neoplasms
- Medical College of Wisconsin, Milwaukee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- The Medical College of Wisconsin, Milwaukee
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT05602363In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
- University of Wisconsin, Madison
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 nov 2025 · NCT04785989Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
In reclutamentoStudio osservazionale
Età da 18 a 80 · Tutti i sessi · Aggiornato il 10 nov 2025 · NCT03375619A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 feb 2025 · NCT06788639Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.